Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine

Standard

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine. / Odak, Ivan; Riemann, Lennart; Sandrock, Inga; Cossmann, Anne; Ramos, Gema Morillas; Hammerschmidt, Swantje I; Ritter, Christiane; Friedrichsen, Michaela; Hassan, Ahmed; Dopfer-Jablonka, Alexandra; Stankov, Metodi V; Weskamm, Leonie M; Addo, Marylyn M; Ravens, Inga; Willenzon, Stefanie; Schimrock, Anja; Ristenpart, Jasmin; Janssen, Anika; Barros-Martins, Joana; Hansen, Gesine; Falk, Christine; Behrens, Georg M N; Förster, Reinhold.

In: EBIOMEDICINE, Vol. 99, 104947, 01.2024.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Odak, I, Riemann, L, Sandrock, I, Cossmann, A, Ramos, GM, Hammerschmidt, SI, Ritter, C, Friedrichsen, M, Hassan, A, Dopfer-Jablonka, A, Stankov, MV, Weskamm, LM, Addo, MM, Ravens, I, Willenzon, S, Schimrock, A, Ristenpart, J, Janssen, A, Barros-Martins, J, Hansen, G, Falk, C, Behrens, GMN & Förster, R 2024, 'Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine', EBIOMEDICINE, vol. 99, 104947. https://doi.org/10.1016/j.ebiom.2023.104947

APA

Odak, I., Riemann, L., Sandrock, I., Cossmann, A., Ramos, G. M., Hammerschmidt, S. I., Ritter, C., Friedrichsen, M., Hassan, A., Dopfer-Jablonka, A., Stankov, M. V., Weskamm, L. M., Addo, M. M., Ravens, I., Willenzon, S., Schimrock, A., Ristenpart, J., Janssen, A., Barros-Martins, J., ... Förster, R. (2024). Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine. EBIOMEDICINE, 99, [104947]. https://doi.org/10.1016/j.ebiom.2023.104947

Vancouver

Bibtex

@article{4fb91010b846470fbe5dcfde7245d6f6,
title = "Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine",
abstract = "BACKGROUND: Human immune responses to COVID-19 vaccines display a large heterogeneity of induced immunity and the underlying immune mechanisms for this remain largely unknown.METHODS: Using a systems biology approach, we longitudinally profiled a unique cohort of female high and low responders to the BNT162b vaccine, who were known from previous COVID-19 vaccinations to develop maximum and minimum immune responses to the vaccine. We utilized high dimensional flow cytometry, bulk and single cell mRNA sequencing and 48-plex serum cytokine analyses.FINDINGS: We revealed early, transient immunological and molecular signatures that distinguished high from low responders and correlated with B and T cell responses measured 14 days later. High responders featured a distinct transcriptional activity of interferon-driven genes and genes connected to enhanced antigen presentation. This was accompanied by a robust cytokine response related to Th1 differentiation. Both transcriptome and serum cytokine signatures were confirmed in two independent confirmatory cohorts.INTERPRETATION: Collectively, our data contribute to a better understanding of the immunogenicity of mRNA-based COVID-19 vaccines, which might lead to the optimization of vaccine designs for individuals with poor vaccine responses.FUNDING: German Center for Infection Research, German Center for Lung Research, German Research Foundation, Excellence Strategy EXC 2155 {"}RESIST{"} and European Regional Development Fund.",
author = "Ivan Odak and Lennart Riemann and Inga Sandrock and Anne Cossmann and Ramos, {Gema Morillas} and Hammerschmidt, {Swantje I} and Christiane Ritter and Michaela Friedrichsen and Ahmed Hassan and Alexandra Dopfer-Jablonka and Stankov, {Metodi V} and Weskamm, {Leonie M} and Addo, {Marylyn M} and Inga Ravens and Stefanie Willenzon and Anja Schimrock and Jasmin Ristenpart and Anika Janssen and Joana Barros-Martins and Gesine Hansen and Christine Falk and Behrens, {Georg M N} and Reinhold F{\"o}rster",
note = "Copyright {\textcopyright} 2023 The Author(s). Published by Elsevier B.V. All rights reserved.",
year = "2024",
month = jan,
doi = "10.1016/j.ebiom.2023.104947",
language = "English",
volume = "99",
journal = "EBIOMEDICINE",
issn = "2352-3964",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine

AU - Odak, Ivan

AU - Riemann, Lennart

AU - Sandrock, Inga

AU - Cossmann, Anne

AU - Ramos, Gema Morillas

AU - Hammerschmidt, Swantje I

AU - Ritter, Christiane

AU - Friedrichsen, Michaela

AU - Hassan, Ahmed

AU - Dopfer-Jablonka, Alexandra

AU - Stankov, Metodi V

AU - Weskamm, Leonie M

AU - Addo, Marylyn M

AU - Ravens, Inga

AU - Willenzon, Stefanie

AU - Schimrock, Anja

AU - Ristenpart, Jasmin

AU - Janssen, Anika

AU - Barros-Martins, Joana

AU - Hansen, Gesine

AU - Falk, Christine

AU - Behrens, Georg M N

AU - Förster, Reinhold

N1 - Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

PY - 2024/1

Y1 - 2024/1

N2 - BACKGROUND: Human immune responses to COVID-19 vaccines display a large heterogeneity of induced immunity and the underlying immune mechanisms for this remain largely unknown.METHODS: Using a systems biology approach, we longitudinally profiled a unique cohort of female high and low responders to the BNT162b vaccine, who were known from previous COVID-19 vaccinations to develop maximum and minimum immune responses to the vaccine. We utilized high dimensional flow cytometry, bulk and single cell mRNA sequencing and 48-plex serum cytokine analyses.FINDINGS: We revealed early, transient immunological and molecular signatures that distinguished high from low responders and correlated with B and T cell responses measured 14 days later. High responders featured a distinct transcriptional activity of interferon-driven genes and genes connected to enhanced antigen presentation. This was accompanied by a robust cytokine response related to Th1 differentiation. Both transcriptome and serum cytokine signatures were confirmed in two independent confirmatory cohorts.INTERPRETATION: Collectively, our data contribute to a better understanding of the immunogenicity of mRNA-based COVID-19 vaccines, which might lead to the optimization of vaccine designs for individuals with poor vaccine responses.FUNDING: German Center for Infection Research, German Center for Lung Research, German Research Foundation, Excellence Strategy EXC 2155 "RESIST" and European Regional Development Fund.

AB - BACKGROUND: Human immune responses to COVID-19 vaccines display a large heterogeneity of induced immunity and the underlying immune mechanisms for this remain largely unknown.METHODS: Using a systems biology approach, we longitudinally profiled a unique cohort of female high and low responders to the BNT162b vaccine, who were known from previous COVID-19 vaccinations to develop maximum and minimum immune responses to the vaccine. We utilized high dimensional flow cytometry, bulk and single cell mRNA sequencing and 48-plex serum cytokine analyses.FINDINGS: We revealed early, transient immunological and molecular signatures that distinguished high from low responders and correlated with B and T cell responses measured 14 days later. High responders featured a distinct transcriptional activity of interferon-driven genes and genes connected to enhanced antigen presentation. This was accompanied by a robust cytokine response related to Th1 differentiation. Both transcriptome and serum cytokine signatures were confirmed in two independent confirmatory cohorts.INTERPRETATION: Collectively, our data contribute to a better understanding of the immunogenicity of mRNA-based COVID-19 vaccines, which might lead to the optimization of vaccine designs for individuals with poor vaccine responses.FUNDING: German Center for Infection Research, German Center for Lung Research, German Research Foundation, Excellence Strategy EXC 2155 "RESIST" and European Regional Development Fund.

U2 - 10.1016/j.ebiom.2023.104947

DO - 10.1016/j.ebiom.2023.104947

M3 - SCORING: Journal article

C2 - 38160529

VL - 99

JO - EBIOMEDICINE

JF - EBIOMEDICINE

SN - 2352-3964

M1 - 104947

ER -